• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

    Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

  2. Pops for Volvo, Roche help propel European stocks higher

    Pops for Volvo, Roche help propel European stocks higher

  3. EUROPE MARKETS: Pops For Volvo, Roche Help Propel European Stocks Higher

    EUROPE MARKETS: Pops For Volvo, Roche Help Propel European Stocks Higher

  4. EUROPE MARKETS: Pops For Volvo, Roche Help Propel European Stocks To Higher Close

    EUROPE MARKETS: Pops For Volvo, Roche Help Propel European Stocks To Higher Close

  5. UPDATE: Pops for Volvo, Roche help propel European stocks to higher close

    UPDATE: Pops for Volvo, Roche help propel European stocks to higher close

  6. UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

    UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

  7. UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

    UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

  8. New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

    New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

  9. UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

    UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

  10. UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

    UPDATE: New competition took a bite out of J&J's drug sales, but don't expect the trend to dominate this earnings season

12

©2017 Morningstar Advisor. All right reserved.